India, Oct. 21 -- Kyverna Therapeutics, Inc. (KYTX) announced one-year results from its registrational Phase 2 KYSA-8 trial, demonstrating sustained clinical benefits of miv-cel in patients with stiff person syndrome (SPS).
The data showed a median 49% improvement in the timed 25-foot walk test at one year. Of the 26 patients treated, 77% achieved clinically meaningful improvement in walking performance, while 92% remained free of chronic immunotherapies for SPS.
Additional findings showed sustained improvements in mobility, disability, muscle stiffness and sensitivity. Among the 12 patients who required walking aids before treatment, eight continued to walk without assistance at one year.
Miv-cel also demonstrated a well-tolerated safet...